Galera Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.19
- Today's High:
- $0.1991
- Open Price:
- $0.1991
- 52W Low:
- $0.19
- 52W High:
- $3.59
- Prev. Close:
- $0.194
- Volume:
- 1212245
Company Statistics
- Market Cap.:
- $9.30 million
- Book Value:
- -2.624
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -64.96%
- Return on Equity TTM:
- -1063.11%
Company Profile
Galera Therapeutics Inc had its IPO on 2019-11-07 under the ticker symbol GRTX.
The company operates in the Healthcare sector and Biotechnology industry. Galera Therapeutics Inc has a staff strength of 31 employees.
Stock update
Shares of Galera Therapeutics Inc opened at $0.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.19 - $0.2, and closed at $0.19.
This is a +0.41% increase from the previous day's closing price.
A total volume of 1,212,245 shares were traded at the close of the day’s session.
In the last one week, shares of Galera Therapeutics Inc have slipped by -8.11%.
Galera Therapeutics Inc's Key Ratios
Galera Therapeutics Inc has a market cap of $9.30 million, indicating a price to book ratio of 29.3902 and a price to sales ratio of 0.
In the last 12-months Galera Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-56746000. The EBITDA ratio measures Galera Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Galera Therapeutics Inc’s operating margin was 0% while its return on assets stood at -64.96% with a return of equity of -1063.11%.
In Q2, Galera Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Galera Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Galera Therapeutics Inc’s profitability.
Galera Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0899. Its price to sales ratio in the trailing 12-months stood at 0.
Galera Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $48.28 million
- Total Liabilities
- $13.62 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $50000
- Dividend Payout Ratio
- 0%
Galera Therapeutics Inc ended 2024 with $48.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $48.28 million while shareholder equity stood at $-114999000.00.
Galera Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $13.62 million in other current liabilities, 44000.00 in common stock, $-416746000.00 in retained earnings and $881000.00 in goodwill. Its cash balance stood at $24.30 million and cash and short-term investments were $38.76 million. The company’s total short-term debt was $128,000 while long-term debt stood at $0.
Galera Therapeutics Inc’s total current assets stands at $42.00 million while long-term investments were $0 and short-term investments were $14.45 million. Its net receivables were $0 compared to accounts payable of $5.52 million and inventory worth $0.
In 2024, Galera Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $50000.
Comparatively, Galera Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.19
- 52-Week High
- $3.59
- 52-Week Low
- $0.19
- Analyst Target Price
- $7.75
Galera Therapeutics Inc stock is currently trading at $0.19 per share. It touched a 52-week high of $3.59 and a 52-week low of $3.59. Analysts tracking the stock have a 12-month average target price of $7.75.
Its 50-day moving average was $1.52 and 200-day moving average was $2.15 The short ratio stood at 0.69 indicating a short percent outstanding of 0%.
Around 955.8% of the company’s stock are held by insiders while 4637.7% are held by institutions.
Frequently Asked Questions About Galera Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.